165 related articles for article (PubMed ID: 18988655)
1. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy.
Jatoi A; Nguyen PL
Oncologist; 2008 Nov; 13(11):1201-4. PubMed ID: 18988655
[TBL] [Abstract][Full Text] [Related]
2. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients.
Nardone B; Nicholson K; Newman M; Guitart J; Gerami P; Talarico N; Yang XJ; Rademaker A; West DP; Lacouture ME
Clin Cancer Res; 2010 Sep; 16(17):4452-60. PubMed ID: 20732960
[TBL] [Abstract][Full Text] [Related]
3. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases.
Fabbrocini G; Panariello L; Cacciapuoti S; Bianca D; Ayala F
Dermatitis; 2012; 23(5):237-8. PubMed ID: 23010833
[TBL] [Abstract][Full Text] [Related]
4. Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis.
Wei F; Shin D; Cai X
Int J Clin Oncol; 2018 Jun; 23(3):443-451. PubMed ID: 29289981
[TBL] [Abstract][Full Text] [Related]
5. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
Jatoi A; Thrower A; Sloan JA; Flynn PJ; Wentworth-Hartung NL; Dakhil SR; Mattar BI; Nikcevich DA; Novotny P; Sekulic A; Loprinzi CL
Oncologist; 2010; 15(9):1016-22. PubMed ID: 20798191
[TBL] [Abstract][Full Text] [Related]
6. Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
Hichert V; Scholl C; Steffens M; Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Oncotarget; 2017 May; 8(21):35193-35204. PubMed ID: 28456787
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Wu PA; Balagula Y; Lacouture ME; Anadkat MJ
Curr Opin Oncol; 2011 Jul; 23(4):343-51. PubMed ID: 21537180
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.
Parmar S; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seeringer A; Paul T; Seufferlein T; Stingl JC
Pharmacogenomics J; 2013 Apr; 13(2):181-8. PubMed ID: 22158333
[TBL] [Abstract][Full Text] [Related]
9. Targeting the epidermal growth factor receptor in colorectal carcinoma.
Kurtin SE
Cancer Nurs; 2007; 30(4 Suppl 1):S1-9. PubMed ID: 17666985
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting.
Gridelli C; Maione P; Amoroso D; Baldari M; Bearz A; Bettoli V; Cammilluzzi E; Crinò L; De Marinis F; Di Pietro FA; Grossi F; Innocenzi D; Micali G; Piantedosi FV; Scartozzi M
Crit Rev Oncol Hematol; 2008 May; 66(2):155-62. PubMed ID: 18083041
[TBL] [Abstract][Full Text] [Related]
11. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
Jatoi A; Rowland K; Sloan JA; Gross HM; Fishkin PA; Kahanic SP; Novotny PJ; Schaefer PL; Johnson DB; Tschetter LK; Loprinzi CL
Cancer; 2008 Aug; 113(4):847-53. PubMed ID: 18543329
[TBL] [Abstract][Full Text] [Related]
12. Nimotuzumab: evidence of clinical benefit without rash.
Allan DG
Oncologist; 2005 Oct; 10(9):760-1. PubMed ID: 16249358
[No Abstract] [Full Text] [Related]
13. [Cutaneous side effects of EGF-receptor inhibition and their management].
Gutzmer R; Werfel T; Kapp A; Elsner J
Hautarzt; 2006 Jun; 57(6):509-13. PubMed ID: 16205868
[TBL] [Abstract][Full Text] [Related]
14. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Pérez-Soler R
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):23-8. PubMed ID: 14682120
[TBL] [Abstract][Full Text] [Related]
15. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
16. Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
Dunsford J
Clin J Oncol Nurs; 2008 Jun; 12(3):405-7. PubMed ID: 18515238
[No Abstract] [Full Text] [Related]
17. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Karamouzis MV; Grandis JR; Argiris A
JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
[TBL] [Abstract][Full Text] [Related]
18. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis.
Jia Y; Lacouture ME; Su X; Wu S
J Support Oncol; 2009; 7(6):211-7. PubMed ID: 20380328
[TBL] [Abstract][Full Text] [Related]
19. Azithromycin pulses for the treatment of epidermal growth factor receptor inhibitor-related papulopustular eruption: an effective and convenient alternative to tetracyclines.
Nikolaou V; Strimpakos AS; Stratigos A; Katsambas A; Antoniou C; Syrigos KN
Dermatology; 2012; 224(4):315-9. PubMed ID: 22699716
[TBL] [Abstract][Full Text] [Related]
20. Predictors of Tumor Response to Cetuximab and Panitumumab in 116 Patients and a Review of Approaches to Managing Skin Toxicity.
Jaka A; Gutiérrez-Rivera A; López-Pestaña A; del Alcázar E; Zubizarreta J; Vildosola S; Arregui MA; Sarasqueta C; Lobo C; Tuneu A
Actas Dermosifiliogr; 2015; 106(6):483-92. PubMed ID: 25798804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
